This study is testing a drug called Zopocianine (OTL78) to see how well it helps doctors find prostate cancer during surgery. Zopocianine is given as an injection 1-7 days before surgery. It works with a special camera (Near InfraRed or NIR fluorescent imaging) to make cancer cells glow, which could help surgeons remove all the cancer. The study is looking for men aged 18 and older who have prostate cancer that is more aggressive (Grade group 3-5) or suspected to have spread outside the prostate. The main goal is to see how many patients have a "Clinically Significant Event" (meaning cancer was found and removed) on the day of surgery. The current status of the study is unclear.

Study design

This is a Phase IIb, open-label study involving up to 36 male participants. It is testing a single dose of Zopocianine.

What's involved

You would receive a single injection of Zopocianine 1-7 days before your prostatectomy and lymph node dissection surgery.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured on the day of surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.